AVPR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL166641	1.00	20/20
Tolvaptan (SCHEMBL242421)	1.00	20/20
SCHEMBL255943	1.00	20/20
SCHEMBL255996	1.00	20/20
SCHEMBL256004	1.00	20/20
SCHEMBL256007	1.00	20/20
SCHEMBL256567	1.00	20/20
SCHEMBL256628	1.00	20/20
SCHEMBL256643	1.00	20/20
SCHEMBL256773	1.00	20/20
SCHEMBL256949	1.00	20/20
SCHEMBL257007	1.00	20/20
SCHEMBL256637	0.89	20/20
SCHEMBL256627	0.86	20/20
SCHEMBL256005	0.84	20/20
SCHEMBL165296	0.82	20/20
SCHEMBL256954	0.82	20/20
SCHEMBL257280	0.82	20/20
SCHEMBL168160	0.81	20/20
SCHEMBL256836	0.81	20/20

Clinical trials — most relevant to AVPR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation	PHASE4	COMPLETED
Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine	PHASE4	WITHDRAWN
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease	PHASE2/PHASE3	COMPLETED
SALT-2 Trial Study of Ascending Levels of Tolvaptan in Hyponatremia	PHASE3	COMPLETED
SALT Trial Study of Ascending Levels of Tolvaptan in Hyponatremia	PHASE3	COMPLETED
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)	PHASE2/PHASE3	COMPLETED
Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls	PHASE2	RECRUITING
Study of Stroke Related Edema Treatments	PHASE2	WITHDRAWN
Efficacy and Safety of VA106483 in Elderly Males	PHASE1/PHASE2	COMPLETED
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)	PHASE2	COMPLETED
Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder	PHASE2	COMPLETED
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	PHASE2	COMPLETED
Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus	PHASE2	RECRUITING
Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls	PHASE2	RECRUITING
The Role of Vasopressin Antagonism on Renal Sodium Handling	PHASE1	COMPLETED
Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation	PHASE1	ACTIVE_NOT_RECRUITING
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)	PHASE1	COMPLETED
The Effect of Vasopressin on Glucose Regulation	nan	COMPLETED
Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock	nan	UNKNOWN
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant	nan	COMPLETED
V2 Receptor Effects on Fluid Regulation and Performance	nan	COMPLETED
From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys	nan	COMPLETED
Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome	nan	RECRUITING
Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study	nan	COMPLETED
Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS)	nan	COMPLETED
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD	nan	COMPLETED
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction	nan	RECRUITING
Fractional Urate Excretion in Nonedematous Hyponatremia	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a AVPR2 binder may also engage these)

Protein	Name	Similarity
O77808	—	1.000	O77808 →
Q00788	—	1.000	Q00788 →
O88721	—	1.000	O88721 →
P48044	—	1.000	P48044 →
P32307	—	1.000	P32307 →
Q95JG1	—	0.977	Q95JG1 →
AVPR1B	Vasopressin V1b receptor	0.976	landscape →
Q95MH6	—	0.972	Q95MH6 →
P32306	—	0.972	P32306 →
Q95MG6	—	0.971	Q95MG6 →
P56494	—	0.967	P56494 →
Q9WU02	—	0.967	Q9WU02 →
P56449	—	0.966	P56449 →
P97926	—	0.966	P97926 →
OXTR	Oxytocin receptor	0.966	landscape →
Q28756	—	0.965	Q28756 →
Q91X56	—	0.964	Q91X56 →
P48974	—	0.964	P48974 →
GALR3	Galanin receptor type 3	0.963	landscape →
Q9JKM5	—	0.963	Q9JKM5 →
S1PR5	Sphingosine 1-phosphate receptor 5	0.963	landscape →
Q684M3	—	0.960	Q684M3 →
P35375	—	0.960	P35375 →
Q8HYC3	—	0.959	Q8HYC3 →
P30936	—	0.959	P30936 →
P70536	—	0.958	P70536 →
PTGIR	Prostacyclin receptor	0.957	landscape →
P30935	—	0.957	P30935 →
O88626	—	0.955	O88626 →
P70597	—	0.955	P70597 →